Cardiovascular disease remains the principal cause of death and disability among patients
with diabetes mellitus. Diabetes mellitus exacerbates mechanisms underlying …

The gene encoding PCSK9 was first identified and linked to the phenotype of familial
hypercholesterolaemia approximately 15 years ago. Soon after, studies uncovered the role …

Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran,
which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …

Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive
statin therapy reduces progression of coronary atherosclerosis in proportion to achieved …

Background Pharmacologic inhibitors of proprotein convertase subtilisin–kexin type 9
(PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease …

Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …

Background Homozygous familial hypercholesterolaemia is a rare, serious disorder caused
by very low or absent plasma clearance of LDL, substantially raised LDL cholesterol, and …

Mendelian Randomization: Methods For Causal Inference Using Genetic Variants provides
thorough coverage of the methods and practical elements of Mendelian randomization …

Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …